Angioedema With Renin Angiotensin System Drugs and Neutral Endopeptidase Inhibitors

In the PARADIGM-HF study, sacubitril-valsartan (LCZ696) was found to be superior to enalapril in reducing the risks of death and hospitalization for heart failure.1 The medication was approved by the FDA for use in patients with chronic NYHA Class II-IV heart failure and reduced ejection fraction. However, questions remain about the use of sacubitril-valsartan across the spectrum of patients with heart failure and on the occurrence of angioedema.2

Source: Journal of the American Society of Hypertension - March 7, 2016 Category: Cardiology Authors: John B. Kostis, Abel E. Moreyra, William J. Kostis Tags: Commentary Source Type: research